In other studies, treatment with Azacitidine has shown a dose-dependent upregulation of PD-L1, PD-L2, PD-1, and, to a lesser extent, CTLA-4 in both AML blasts and T-cells, and it was linked to a shorter duration of response and a trend towards lower OS [171,172,173]. This evidence concerns the gene CD274 and acute myeloid leukemia.